That American investors have deep pockets is a widely held belief in biopharma, and in fairness it is generally true. But that doesn’t mean they are careless with their cash.
Key Takeaways
- Telix cancelled its NASDAQ IPO the morning shares were due to start trading, saying US investors were not willing to pay the price it sought.
- The group...
Radiopharmaceutical player Telix Pharmaceuticals Ltd.’s decision to yank its proposed NASDAQ IPO at the very last minute appears to have resulted from putative investors’ refusal to buy at the...